Brief: 4Dmt Completes Enrollment For 4Front-1 Phase 3 Clinical Trial Of 4D-150 In Wet AMD
09/02/2026 14:59
Feb 9 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O: 4DMT COMPLETES ENROLLMENT FOR 4FRONT-1 PHASE 3 CLINICAL TRIAL OF 4D-150 IN WET AMD Source text: ID:nGNX2ZHj4m Further company coverage: FDMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all newsBrief: 4D Molecular Therapeutics Q1 Net Income USD -68.76 Million Vs. IBES Estimate USD -62.6 Million
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Brief: 4Dmt Completes Enrollment For 4Front-1 Phase 3 Clinical Trial Of 4D-150 In Wet AMD
Brief: 4Dmt Provides Company Update And Anticipated Development Milestones For 2026
U.S. RESEARCH ROUNDUP-Cencora, Eagle Materials, Honeywell